SHANGHAI – Epimab Biotherapeutics Inc., of Shanghai, now has $25 million in its coffers to put its lead candidate into clinical development, a bispecific antibody for oncology.
SHANGHAI – Epimab Biotherapeutics Inc., of Shanghai, now has $25 million in its coffers to put its lead candidate into clinical development, a bispecific antibody for oncology. The series A investors hail from China, the U.S. and the U.K., with Oriza Seed Capital taking the lead in addition to Decheng Capital, 3E Bioventures and Trend Investment Group.
SHANGHAI – Chinese vaccine developer Cansino Inc., of Tianjin, has received $65 million in a financing round led by Future Industry Investment Fund to hasten the development of its later-stage vaccines and get a new vaccine plant up and running.
SHANGHAI – Chinese vaccine developer Cansino Inc., of Tianjin, has received $65 million in a financing round led by Future Industry Investment Fund to hasten the development of its later-stage vaccines and get a new vaccine plant up-and-running.
SHANGHAI – Shanghai-based biotech Zai Labs Ltd. is adding biologics manufacturing capabilities to its business model of developing new drugs for China via in-licensing assets and in-house biologics discovery.
SHANGHAI – Shanghai-based biotech Zai Labs Ltd. is adding biologics manufacturing capabilities to its business model of developing new drugs for China via in-licensing assets and in-house biologics discovery. The site will be located in Suzhou Biobay and will make clinical trial quantity Biotherapeutics, with the possibility of scaling to commercial quantities at a later stage.
SHANGHAI – Suzhou-based Innovent Biologics Inc. and Hanmi Pharmaceuticals Co. Ltd., of Seoul, South Korea, will pair up to co-develop and co-commercialize a bispecific immuno-oncology antibody for breast cancer with the possibility of other indications to follow. The molecule is expected to enter clinical trials in 2019.
SHANGHAI – At the recent China Healthcare Investment Conference (CHIC) – where investors and Chinese biotech CEOs meet up to try and make their investment dreams come true – the theme was growth vs. innovation. Whether innovation stems from growth or growth comes from other drivers, both appear to be significantly helped along by the recent spate of CFDA regulatory reforms.
SHANGHAI – At the recent China Healthcare Investment Conference (CHIC) – where investors and Chinese biotech CEOs meet up to try and make their investment dreams come true – the theme was growth vs. innovation. Whether innovation stems from growth or growth comes from other drivers, both appear to be significantly helped along by the recent spate of CFDA regulatory reforms.
SHANGHAI – Suzhou-based Innovent Biologics Inc. and Hanmi Pharmaceuticals Co. Ltd., of Seoul, South Korea, will pair up to co-develop and co-commercialize a bispecific immuno-oncology antibody for breast cancer with the possibility of other indications to follow. The molecule is expected to enter clinical trials in 2019.
